Breast cancer risk may persist years after menopausal HT
Women who initiated systemic hormone therapy around the time of menopause were at greater risk for invasive breast cancer than similar never-users, according to an analysis of nearly 60 epidemiologic studies published in The Lancet.
Results showed the increased risk doubling for women who used hormone therapy for 10 years vs. 5 years and some excess risk persisting more than a decade after stopping therapy.
“The totality of the worldwide evidence shows that breast cancer risk is increased while women use menopausal hormone therapy and also after they stop taking it,” Valerie Beral, DBE, FRS, FRCOG, FMedSci, professor of epidemiology and co-director of the cancer epidemiology unit at the University of Oxford in England, told Endocrine Today. “This means that the absolute risk is greater than previously thought. For example, 5 years of menopausal HT, starting at age 50 years, would increase breast cancer incidence from ages 50 to 69 years by about one additional case in every 50 users of estrogen plus daily progestogen HT, one in every 70 users of estrogen plus intermittent progestogen HT, and one in every 200 users of estrogen-only HT."
Beral and colleagues analyzed individual participant data from 58 studies, including 24 prospective cohort studies, conducted between January 1992 and January 2018 that assessed the type and timing of menopausal HT use (mean age at menopause, 50 years; mean age at HT initiation, 50 years). Current users were included up to 5 years (mean, 1.4 years) after last-reported menopausal HT use. Researchers used a nested, case-control design, comparing estrogen alone vs. never use and combination therapy vs. never use. Each women with a diagnosis of invasive breast cancer was matched with four controls by age, birth year and geographic location. Researchers used logistic regression analysis to estimate adjusted risk ratios for breast cancer, comparing menopausal HT users with never users.
Among women with complete information, mean menopausal HT duration was 10 years for current users and 7 years for past users. During prospective follow-up, 108,647 women developed breast cancer at a mean age of 65 years. Among these women, 55,575 (51%) had used menopausal HT.
Longer use, greater risk
Researchers found that every menopausal HT type, apart from vaginal estrogens, was associated with excess breast cancer risk, which increased steadily with duration of use and was greater for estrogen-progestogen than estrogen-only preparations. Among current users, excess risks were observed even during years 1 to 4, with an RR of 1.6 (95% CI, 1.52-1.69) for estrogen-progestogen preparations and 1.17 (95% CI, 1.1–1.26) for estrogen-only preparations. This risk doubled for current users during years 5 to 14, with RRs of 2.08 (95% CI, 2.02-2.15) for estrogen-progestogen preparations and 1.33 (95% CI, 1.28-1.37) for estrogen-only preparations.
The researchers noted that the estrogen-progestogen risks during years 5 to 14 were greater with daily vs. less frequent progestogen use, with RRs of 2.3 (95% CI, 2.21-2.4) vs. 1.93 (95% CI, 1.84-2.01; P < .0001 for heterogeneity).
For a given preparation, the RRs during years 5 to 14 of current use were greater for estrogen-receptor-positive tumors vs. estrogen-receptor-negative tumors. Risks for breast cancer were similar for women initiating menopausal HT at ages 40 to 44, 45 to 49, 50 to 54, and 55 to 59 years, but attenuated by starting after age 60 years or by adiposity.
“Although use of either type of [menopausal] HT for less than 1 year was associated with little subsequent risk, for women of average weight in developed countries, 5 years of use, starting at age 50 years, would cause an appreciable increase in the probability of developing breast cancer at ages 50-69 years,” the researchers wrote. “About half the excess would be during the first 5 years of current use of [menopausal] HT, and half would be during the next 15 years of past use.”
The researchers estimated that the absolute increase would be about 2 cases per 100 women (one in every 50 users) for estrogen plus daily progestogen, 1.4 per 10 women (one in 70 users) for estrogen plus intermittent progestogen and 0.5 per 100 women (one in 200 users) for estrogen-only HT.
Assess risks and benefits
In a commentary accompanying the study, Joanne Kotsopoulos, PhD, a scientist at Women’s College Research Institute and associate professor at the Dalla Lana School of Public Health at the University of Toronto, noted that the main analysis was limited to prospective studies with detailed information on HT use and adjusted for potential confounders.
“The complexity of the study design makes it difficult to appraise the results, and most of us will take the results on face value,” Kotsopoulos wrote. “However, it is often difficult to avoid biases in prospective studies in which the period of exposure (HT use) overlaps with the period of risk (breast cancer incidence). Some women switch from being nonusers to users in the follow-up, and the duration of use is not a constant but changes each year that hormones are used.”
According to Kotsopoulos, clinicians should take a “rational and comprehensive approach” to the management of menopausal symptoms, with careful consideration of the risks and benefits of initiating menopausal HT for each woman.
“This might be dependent on severity of the symptoms, contraindications for [menopausal] HT (ie, breast cancer, cardiovascular disease and stroke), and BMI, and could take into account patient preference,” Kotsopoulos wrote. “For likely candidates, [menopausal] HT (preferably estrogen alone) should be initiated around the time of natural menopause and ideally limited to 5 years of use.”
As Endocrine Today previously reported, a case-control analysis published in PLOS ONE suggested that current use of menopausal HT may double the risk for developing several hormone receptor-positive breast cancers. In an analysis of more than 700 women using data from the New South Wales Cancer, Lifestyle and Evaluation of Risk (CLEAR) study, researchers found that, compared with never use of HT, current use of menopausal HT was associated with a twofold increased risk for developing estrogen receptor-positive breast cancer (adjusted OR = 2.04; 95% CI, 1.28-3.24), as well as estrogen and progesterone receptor-positive breast cancer (aOR = 2.29; 95% CI, 1.41-3.72). Additionally, current menopausal HT use was associated with increased risk for developing estrogen and progesterone receptor-positive and human epidermal growth factor receptor-2-negative (HER-2-negative) breast cancer (aOR = 2.3; 95% CI, 1.42-3.73) vs. never use of HT. In that analysis, past menopausal HT use was not associated with breast cancer incidence. – by Regina Schaffer
Disclosures: The authors report no relevant financial disclosures. Kotsopoulos reports no relevant financial disclosures.